23andMe, once valued at $6 billion, has seen its worth plummet by 98% and is at risk of being delisted from Nasdaq after the resignation of all independent board members. The company, which aimed to innovate genetic testing and drug discovery, reported a $312 million net loss in 2023, compounded by privacy concerns following a data breach affecting nearly 7 million customers. CEO Anne Wojcicki's proposal to take the company private was rejected, and with a looming deadline to maintain its share price above $1, 23andMe faces significant challenges ahead.